Pay in 4 interest-free payments of $7.25 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Phase 1b: Multiple Ascending Dose Study (NCT03014609) Study Title: "Safety, Tolerability, PK and PD of Multiple Doses of Cagrilintide in Subjects With Type 2 Diabetes" Status: Completed Phase: Phase 1b Enrollment: 56 participants with T2D Study Period: 2017-2018 Design: Randomized, double-blind, placebo-controlled Duration: 12 weeks Dose Range: 0.3-4.5 mg SC weekly Population: T2D, BMI 25-40, HbA1c 7-10% Key Results: Weight Loss: 6.0 kg (4.5 mg dose) vs
The degradation begins immediately upon contact with the nasal mucosa and continues throughout the absorption process
These products are not for human consumption, veterinary use, or any other application involving living organisms, including but not limited to diagnostic, therapeutic, or recreational purposes
Let it soak overnight
US$ 22.45
US$ 26.77
US$ 24.76
